Current MPS1 treatments include IDUA enzyme replacement therapy (ERT) (Aldurazyme) via intravenous injections, which has proven useful in reducing hepatosplenomegaly, and in improving myocardiac function, pulmonary symptoms and motility in MPS1 patients with mild disease. Here, IDUA is linked to Hepatosplenomegaly.